Cyclo Therapeutics, Inc. Stock: price and insider trades · United States

In competitive terms, Cyclo Therapeutics is best viewed as a niche rare-disease biotech rather than a broad commercial pharmaceutical company. Its differentiation lies in the underlying mechanism and in the depth of its clinical work in NPC1, a disease area where few companies operate and where treatment options remain limited. The company states that Trappsol® Cyclo™ has orphan-drug designation in both the United States and Europe, which could be strategically important if the asset ultimately gains approval. Importantly, the product is not currently approved for any indication, so the equity story remains development-stage and event-driven.

Recent corporate developments have been material. Cyclo Therapeutics has advanced its TransportNPC™ phase 3 program, including the reporting of preliminary data from an open-label sub-study in patients younger than three years old. The company also announced an agreement and plan of merger with Rafael Holdings in 2024, and later disclosed that the merger was completed following shareholder approvals in March 2025. As a result, investors should assess Cyclo Therapeutics not only as a Nasdaq-listed U.S. biotech, but also as an asset whose strategic trajectory has been shaped by a combination of clinical execution and corporate combination with Rafael.

For French, Belgian and Swiss investors, Cyclo Therapeutics represents a classic small-cap biotechnology exposure: scientifically differentiated, clinically focused, and potentially value-creating, but with elevated binary risk tied to trial data, financing needs, and regulatory decisions.